Cencora, Inc.
No SEC Form 4 filings for $COR in the last 30 days.
Cencora Inc (COR) stock rose 3.6% to $274.91, but is still considered 5.4% undervalued based on its GF Value™ of $290.62. The company holds an above-average GF Score™ of 79/100, with a perfect 10/10 in Valuation, despite weaker short-term momentum and no recent insider transactions. Its current P/E ratio is also below its 5-year median, suggesting it might be an attractive long-term investment.
Cencora (NYSE: COR) has updated its fiscal year 2026 financial guidance, increasing its adjusted diluted earnings per share outlook to a range of $17.70 to $17.90 following opportunistic share repurchases in May. Additionally, the company's Board of Directors authorized a new $2.0 billion share repurchase program, reinforcing its commitment to returning value to shareholders. These actions align with Cencora's strategy to optimize market access for pharmaceutical innovators and deliver healthcare products.
Cencora, formerly AmerisourceBergen, is undergoing a strategic transformation with solid earnings and guidance, maintaining its position as a key pharmaceutical distributor. The company focuses on logistics, specialty pharmaceutical services, and manufacturer support, showing continued demand and strategic expansion into higher-value segments. Key factors for investors include its stable cash flows, capital-return policies, and sensitivity to US healthcare policy and regulatory changes.
